These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 29854415)

  • 41. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
    Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
    Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adherence to disease-modifying therapies and attitudes regarding disease in patients with multiple sclerosis.
    Ožura A; Kovač L; Sega S
    Clin Neurol Neurosurg; 2013 Dec; 115 Suppl 1():S6-11. PubMed ID: 24321157
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of diagnosis and early treatment on the course of multiple sclerosis.
    Noyes K; Weinstock-Guttman B
    Am J Manag Care; 2013 Nov; 19(17 Suppl):s321-31. PubMed ID: 24494633
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort study.
    Zhornitsky S; Greenfield J; Koch MW; Patten SB; Harris C; Wall W; Alikhani K; Burton J; Busche K; Costello F; Davenport JW; Jarvis SE; Lavarato D; Parpal H; Patry DG; Yeung M; Metz LM
    PLoS One; 2015; 10(4):e0123824. PubMed ID: 25867095
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Relapse prevalence, symptoms, and health care engagement: patient insights from the Multiple Sclerosis in America 2017 survey.
    Nazareth TA; Rava AR; Polyakov JL; Banfe EN; Waltrip Ii RW; Zerkowski KB; Herbert LB
    Mult Scler Relat Disord; 2018 Nov; 26():219-234. PubMed ID: 30368080
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study.
    Steinberg SC; Faris RJ; Chang CF; Chan A; Tankersley MA
    Clin Drug Investig; 2010; 30(2):89-100. PubMed ID: 20067327
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Objective medication adherence and persistence in people with multiple sclerosis: a systematic review, meta-analysis, and meta-regression.
    Mardan J; Hussain MA; Allan M; Grech LB
    J Manag Care Spec Pharm; 2021 Sep; 27(9):1273-1295. PubMed ID: 34464209
    [No Abstract]   [Full Text] [Related]  

  • 48. Sustained disease remission after discontinuation of disease modifying treatments in relapsing-remitting multiple sclerosis.
    Pasca M; Forci B; Mariottini A; Mechi C; Barilaro A; Massacesi L; Repice AM
    Mult Scler Relat Disord; 2021 Jan; 47():102591. PubMed ID: 33142245
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Low-fat, plant-based diet in multiple sclerosis: A randomized controlled trial.
    Yadav V; Marracci G; Kim E; Spain R; Cameron M; Overs S; Riddehough A; Li DK; McDougall J; Lovera J; Murchison C; Bourdette D
    Mult Scler Relat Disord; 2016 Sep; 9():80-90. PubMed ID: 27645350
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The impact of comorbid depression on adherence to therapy for multiple sclerosis.
    Tarrants M; Oleen-Burkey M; Castelli-Haley J; Lage MJ
    Mult Scler Int; 2011; 2011():271321. PubMed ID: 22096632
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adherence and persistence to drug therapies for multiple sclerosis: A population-based study.
    Evans C; Marrie RA; Zhu F; Leung S; Lu X; Melesse DY; Kingwell E; Zhao Y; Tremlett H
    Mult Scler Relat Disord; 2016 Jul; 8():78-85. PubMed ID: 27456879
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lack of magnetic resonance imaging lesion activity as a treatment target in multiple sclerosis: An evaluation using electronically collected outcomes.
    Conway DS; Thompson NR; Cohen JA
    Mult Scler Relat Disord; 2016 Sep; 9():129-34. PubMed ID: 27645360
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis.
    Devonshire V; Lapierre Y; Macdonell R; Ramo-Tello C; Patti F; Fontoura P; Suchet L; Hyde R; Balla I; Frohman EM; Kieseier BC;
    Eur J Neurol; 2011 Jan; 18(1):69-77. PubMed ID: 20561039
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy.
    Kister I; Spelman T; Patti F; Duquette P; Trojano M; Izquierdo G; Lugaresi A; Grammond P; Sola P; Ferraro D; Grand'Maison F; Alroughani R; Terzi M; Boz C; Hupperts R; Lechner-Scott J; Kappos L; Pucci E; Hodgkinson S; Solaro C; Butzkueven H
    J Neurol Sci; 2018 Aug; 391():72-76. PubMed ID: 30103975
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Discontinuation of disease-modifying therapies in multiple sclerosis - Clinical outcome and prognostic factors.
    Bsteh G; Feige J; Ehling R; Auer M; Hegen H; Di Pauli F; Deisenhammer F; Reindl M; Berger T
    Mult Scler; 2017 Aug; 23(9):1241-1248. PubMed ID: 27765877
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Therapy satisfaction and adherence in patients with relapsing-remitting multiple sclerosis: the THEPA-MS survey.
    Haase R; Kullmann JS; Ziemssen T
    Ther Adv Neurol Disord; 2016 Jul; 9(4):250-63. PubMed ID: 27366231
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Age and sex as determinants of treatment decisions in patients with relapsing-remitting MS.
    Sorensen PS; Kopp TI; Joensen H; Olsson A; Sellebjerg F; Magyari M
    Mult Scler Relat Disord; 2021 May; 50():102813. PubMed ID: 33578207
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Patient perspective on decisions to switch disease-modifying treatments in relapsing-remitting multiple sclerosis.
    Manzano A; Eskyté I; Ford HL; Pavitt SH; Potrata B; Schmierer K; Chataway J; Webb EJD; Meads D; Pepper G; Bekker HL
    Mult Scler Relat Disord; 2020 Nov; 46():102507. PubMed ID: 32979733
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS.
    Vermersch P; Oh J; Cascione M; Oreja-Guevara C; Gobbi C; Travis LH; Myhr KM; Coyle PK
    Mult Scler Relat Disord; 2020 Aug; 43():102158. PubMed ID: 32470857
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.